Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biogen, Icos deal

ICOS will reacquire rights to the LFA-1 program it had partnered with BGEN in

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE